Blepharitis Market Size, Share, Growth, And Industry Analysis by Type (Antibiotics, Steroids and Other) by Application (Monotherapy and Combination Drug Therapy), Regional Insights, and Forecast To 2031

Updated On: 10 June 2024

Blepharitis Market Report Overview

• 
• to learn more about this report

The global blepharitis market size was USD 1509 million in 2021 and market is projected to touch USD 2307.04 million by 2031, exhibiting a CAGR of 4.3% during the forecast period.

Inflammation of the eyelid due to blepharitis, an ophthalmological ailment that affects people of all ages, causes ocular pain and eye irritation. Numerous factors, including germs, skin conditions like dandruff from the scalp, and excessive oil production from the glands in the eyelids, can contribute to this eye problem. Although this condition does not endanger eyesight, it might cause permanent changes to the edge of the eyelids or vision loss due to ulceration, superficial keratopathy, and corneal neovascularization. The two forms of blepharitis, anterior and posterior, cause diverse types of eye infection. The skin of the eyelids, the base of the eyelashes, and the eyelash follicles are all affected by the second form, anterior blepharitis. Meibomian gland orifices and posterior blepharitis are both afflicted. Using therapeutic chemicals that lessen infection and irritation, this therapy includes frequent eyelid cleansing practices.

Utilizing therapies or medications during therapy increases treatment effectiveness and opens up new diagnostic and therapeutic possibilities for the patient. A few prevalent forms of eye illnesses can be treated more effectively with the help of this medication. 37% to 47% of patients had blepharitis, according to a survey by the American Academy of Ophthalmology from US ophthalmologists and optometrists. A significant driver of the expansion of the blepharitis market size is the population's blepharitis prevalence and rising treatment awareness. The blepharitis market share is expanding as a result of increased consumer disposable income and rising spending on the construction of healthcare infrastructure. Additionally, increasing biotechnology and pharmaceutical company R&D efforts to produce innovative medications and treatments may open up attractive market expansion prospects. The value of the blepharitis market will also increase as a result of exposure to specific toxins.

COVID-19 Impact: Market Sees Slump In Sales Due To Lockdown Restrictions

The COVID-19 pandemic has had a significant negative impact on the economy and all commercial sectors throughout the world. There are three main factors that have an influence on the economy: first, how they affect supply and demand, second, how they disrupt supply chains and marketplaces, and third, how they have an economic impact on businesses and financial markets. Several nations enforced lockdowns and other stringent laws to stop the coronavirus from spreading.

The COVID-19 lockdown has had an impact on a number of areas, including airline cancellations, transit restrictions, quarantines, and closures of public venues including restaurants, theatres, schools, and any indoor events in order to preserve social distance between individuals. These limitations are in place in more than 40 nations, and the blepharitis manufacturing sectors confront a number of challenges, including a lack of raw materials, a labour shortage, supply chain disruptions, and production halts, which contribute to a decline in blepharitis. As a result, the market for blepharitis is falling due to the stoppage of manufacturing, waning corporate confidence, increased public worry, and individuals remaining at home. However, after the lockdown is lifted, blepharitis treatments become more popular because of their advantages.

Latest Trends

"Market For Blepharitis Is Quickly Expanding As A Result Of The Development Of Medication And Surgical Therapies"

The market for blepharitis is expanding quickly as a result of the development of medication and surgical therapies. Since blepharitis can be a challenging illness to cure, there is a growing desire for novel and cutting-edge therapies. But a number of developments are having an effect on the blepharitis market growth. A multitude of variables, including an ageing population, more knowledge of the ailment, and improved diagnoses, are to blame for this. The market for blepharitis therapies is thus anticipated to expand. Treatments are becoming more advanced and minimally invasive. This is because blepharitis may be a challenging illness to cure and frequently necessitates numerous treatments. Patients are thus increasingly searching for therapies that are less likely to cause pain and more efficient.

The marketplace is getting more cutthroat. This is as a result of several new therapies being developed and an increase in businesses providing blepharitis treatments. As a result, businesses are vying for blepharitis market share, which is probably going to result in cheaper costs and better treatments. The emphasis on patient education is also growing. This is because blepharitis may be a challenging illness to cure and frequently necessitates numerous treatments. Patients must thus be informed about the illness, its causes, and its therapies.

Blepharitis Market SEGMENTATION

• 
• to learn more about this report

• By type

Depending on blepharitis given are types: Antibiotics, Steroids and Other. The Antibiotics type will capture the maximum market share through 2031.

• By Application

The market is divided in Monotherapy and Combination Drug Therapy based on application. The global blepharitis market players in cover segment like Monotherapy will dominate the market share during 2031.

Driving Factors

"Creation Of New Drug Formulations To Boost Market Growth "

Since there are no new, FDA-approved medications available on the market to treat blepharitis, antibiotics and steroids are the most often utilised medications. However, there remains a sizable unmet need for innovative medicines that are more effective and have fewer adverse effects. As a result, several businesses are creating cutting-edge remedies to cure blepharitis. For instance, the unique, patented ocular solution of nanocrystals compound NCX 4261 (fluticasone propionate) is being developed by Nicox SA (Nicox). It is a targeted topical therapy for individuals with acute blepharitis exacerbations on the edges of the eyelids. A swab can be used to apply NCX 4261 directly to the inflamed location. This reduces the likelihood that the medication will enter the cornea, which might cause the harmful side effects linked to today's off-label steroids. As a result, these medicinal improvements are anticipated to boost blepharitis market growth throughout the anticipated timeframe.

"Rising Ocular Ailments Is Anticipated To Have Substantial Expansion On The Market For Blepharitis Therapy"

Due to the rising frequency of ocular problems among the older population, the market for blepharitis therapy is anticipated to expand rapidly in the next years. Inflammation of the eyelids is a characteristic of the common eye illness blepharitis. It can make your eyes red, itchy, burning, and teary. Both acute and chronic blepharitis are possible. While chronic blepharitis is frequently brought on by allergies or autoimmune diseases, acute blepharitis is typically brought on by bacteria. Topical antibiotics or steroidal ointments are frequently used as blepharitis treatments.

Oral antibiotics may also be recommended in specific circumstances. In extreme circumstances, surgery can be necessary. Blepharitis often affects adults over the age of 50, per a 2014 poll by the American Academy of Ophthalmology. Blepharitis is seen in 47% of female and 37% of male ophthalmic patients, according to the same source. The blepharitis market share is anticipated to experience considerable expansion as a result of the growing number of medications in development. For instance, phase 3 clinical studies are ongoing for the medication ISV-305, which is sponsored by InSite Vision. Individuals who have blepharitis' early symptoms are treated with ISV-305.

Restraining Factors

"Antimicrobial Resistance, The Emergence Of New Therapeutic Methods, And The Scarcity Of Authorized Medicines For The Treatment Of Blepharitis "

For ophthalmologists, a difficulty is the development of innovative therapeutic methods, antibiotic resistance, and a lack of authorized medicines to treat blepharitis. Topical antibiotics are the most popular blepharitis treatments, however there isn't enough proof to recommend them. The use of topical antibiotics also raises serious concerns about the emergence of antimicrobial resistance. The most successful treatments for blepharitis are frequently off-label, and there are presently no authorized medications for the condition. Ophthalmologists face a significant problem in managing this illness as a result.

Blepharitis Market Regional Insights

• 
• to learn more about this report

"Largest Market Share Will Belong To And Be Dominated By Europe"

Due to the widespread nature of blepharitis, there is a sizable market in Europe for therapies. The most often used therapies are ointments and lotions that may be administered topically to the eyelids. Oral medications, on the other hand, are also an option for treating the illness. The European blepharitis market is very competitive, offering a wide range of brands and products. Customers may find it challenging to decide which product to buy as a result. However, there are certain broad market tendencies that may be seen. In the market for blepharitis, natural and organic products are becoming more popular. This is because standard medicines' negative effects are causing a lot of individuals to worry more. Many people believe that natural and organic products are safer and kinder to the skin. As blepharitis gains more public awareness, the blepharitis market size is anticipated to expand in the coming years. This will probably encourage greater investigation into fresh, more potent therapies.

Due to the rising elderly population, the introduction of new products, and the rising number of ophthalmology patients in the area, North America is predicted to keep a dominating position in the blepharitis treatment market. The U.S. population's ageing population grew by 24% in 2016 compared to 15% in 2014, according to a survey done by the U.S. Population Reference Bureau. Due to an increase in product launches in the region. As an illustration, in 2017 Scope Ophthalmic introduced the Moist Heat Mask, a device that aids in the treatment of blepharitis by releasing the oil contained in Meibomian glands and enabling it to flow more freely. It aids in reducing eye lash debris, stops natural tear film from evaporating, replenishing moisture to the eye and its surroundings, and enhances the lipid quality of the tear film. A U.S.-based startup called MiBo Medical Group introduced MibO Thermoflo in 2015. This gadget, which aids in the treatment of dry eyes and blepharitis, must be gently rubbed on the eyelid margins for at least 12 minutes. The MiBo Medical Group introduced Lid Pro, a device for the treatment of anterior blepharitis, in 2015.

Key Industry Players

"Key Players Focus on Partnerships to Gain a Competitive Advantage "

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.

List of Market Players Profiled

• Bausch Health (Canada)
• Allergan (Ireland )
• Novartis  (Switzerland)
• LABORATORIES THEA (France)
• Akorn (U.S)
• NovaBay Pharmaceuticals (U.S)
• Scope Ophthalmics (U.K)

Report Coverage

This research profiles a report with extensive studies that take into description the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, and restraints. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.